Home / Market News / $UTHR
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

BTIG Raises Price Target on United Therapeutics

Nov 4, 2026, 11:11 PM UTC · Primary ticker $UTHR

BTIG has increased its price target for United Therapeutics from $728 to $768, maintaining a Buy rating. This adjustment suggests a potential upside of 27.7% from the stock's closing price on November 3, 2026, reflecting a positive outlook on the company's market position.

Investment firm BTIG has raised its price target for United Therapeutics (UTHR) from $728 to $768, while reiterating a 'Buy' rating. This 5.5% increase in the target price signals a positive outlook on the company's market position and implies a potential upside of approximately 27.7% from the stock's closing price on November 3, 2026. For traders, this could lead to short-term positive sentiment and increased buying interest in UTHR, as analysts' price target adjustments often influence investor perception. The long-term implications depend on whether the company's fundamentals and future performance align with BTIG's optimistic valuation, but for now, it presents an opportunity for those looking for upward momentum.

$UTHR positive Price target increase and maintained Buy rating
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.